Sort
10,766 grants matching “checkpoint inhibitor”
Project 1: Targeting the Neutrophil Lineage To Enhance Immune Checkpoint Inhibitor Efficacy in NSCLC
$450,659A. McGarry Houghton · Fred Hutchinson Cancer Research Center · P50 · FY2020 · CA
Targeting NQO1+ tumor to trigger innate and adaptive immunity
$450,508Xiumei Huang · Indiana University Indianapolis · R01 · FY2022 · CA
MUC1-C is a target for advancing immunotherapy of non-small cell lung cancer
$450,429Donald W. Kufe · Dana-Farber Cancer Inst · R21 · FY2024 · CA
Developing macrophage-based therapies for peripheral nerve injuries
$450,313Brett M. Morrison · Johns Hopkins University · R21 · FY2023 · NS
Racial differences in Immunogenetic Tumorigenesis of Head and Neck Squamous Cell Carcinoma
$450,013David Sidransky · Johns Hopkins University · R01 · FY2024 · CA
Cell-type specific inactivation of sumoylation during mouse spermatogenesis
$450,000Margarita Vigodner · Yeshiva University · R15 · FY2019 · HD
Expanding the tumor antigen landscape and maintaining APCs in a T cell-activating state to restore tumor immunity
$449,997Eduardo Davila · University Of Colorado Denver · R01 · FY2024 · CA
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
$449,910Maninder Sandey · Auburn University At Auburn · R15 · FY2023 · CA
Duke-UNC Chapel Hill Immunotherapy Training Grant
$449,807Jonathan Stuart Serody · Univ Of North Carolina Chapel Hill · T32 · FY2018 · CA
Targeting autophagy to enhance immune checkpoint inhibition
$449,729Ravi K Amaravadi · Wistar Institute · P50 · FY2023 · CA
Proteomic determinants of response to checkpoint blockade in malignant pleural mesothelioma
$449,641Bryan Michael Burt · University Of California Los Angeles · R37 · FY2025 · CA
Modulation of tumor inflammatory factor for immune therapy
$449,561Shu-Hsia Chen · Methodist Hospital Research Institute · R01 · FY2019 · CA
Project 3: Investigating new treatment approaches based on DNA repair vulnerability in ARID1A mutated type I ovarian cancer
$449,464Stephanie Gaillard · Johns Hopkins University · P50 · FY2024 · CA
Genome-wide networks that modulate the T-lineage cell fate
$449,375Cornelis Murre · Research Inst Of Fox Chase Can Ctr · P01 · FY2015 · AI
DNA Methylation Inhibitor Therapy for Testicular Cancer
$449,298Michael J Spinella · University Of Illinois At Urbana-Champaign · R01 · FY2020 · CA
Targeting the PD-1H (VISTA) Pathway to Overcome Immunosuppression in Acute Myeloid Leukemia
$449,222Xue Han · Ohio State University · R37 · FY2025 · CA
Intrapleural immunotherapeutic nanoparticles for MPE treatment
$449,180Dawen Zhao · Wake Forest University Health Sciences · R01 · FY2023 · CA
Intrapleural immunotherapeutic nanoparticles for MPE treatment
$449,180Dawen Zhao · Wake Forest University Health Sciences · R01 · FY2022 · CA
Preclinical Development of First-in-Class NDUFS7 Antagonists for the Treatment of Pancreatic Cancer
$449,119Nouri Neamati · University Of Michigan At Ann Arbor · R01 · FY2024 · CA
Defining and Targeting Homologous Recombination Deficiency in Breast Cancer
$449,058Simon N Powell · Sloan-Kettering Inst Can Research · P50 · FY2022 · CA
Development Therapeutics Branch Clinical Trials
$449,053Yves Pommier · Division Of Basic Sciences - Nci · ZIA · FY2025 · CA
Novel mechanisms regulating PD-1 signaling and function
$448,861Adam Mor · Columbia University Health Sciences · R01 · FY2024 · AI
Nutrient sensing and lysosomal signaling in regulatory T cells and immune tolerance
$448,750Hongbo Chi · St. Jude Children'S Research Hospital · R01 · FY2022 · AI
Nutrient sensing and lysosomal signaling in regulatory T cells and immune tolerance
$448,750Hongbo Chi · St. Jude Children'S Research Hospital · R01 · FY2023 · AI
Stroma penetrating and immune modulating nanoparticles for image-guided therapy of pancreatic cancer
$448,604Lily Yang · Emory University · R01 · FY2024 · CA